SC-ENVIVA-FOREST-FUND
20.9.2022 18:04:36 CEST | Business Wire | Press release
The Enviva Forest Conservation Fund (the Fund) today announced the recipients of its 2022 grants. The projects funded this year will help conserve more than 3,000 acres and protect ecologically sensitive bottomland hardwood forests in the Virginia-North Carolina coastal plains.
Including those announced today, the Fund has awarded 29 projects totaling more than $3,100,000 in grants over the past seven years. An estimated 33,000 acres will be protected when these projects reach completion. The forests conserved as a part of the Fund help clean drinking water, purify the air, buffer structures from storms, and provide habitat for many species of wildlife, while at the same time, providing jobs and economic opportunity for rural families and private landowners.
“The fund is well on its way to achieving its initial goal to protect over 35,000 acres of sensitive bottomland hardwood forests across Virginia and South Carolina,” said Thomas Meth, President of Enviva. “With more than three years left in the program, the Fund is poised to partner with more and more diverse conservation groups as well as supersede our commitment to long-term investments in forest stewardship for generations to come.”
The 2022 Enviva Forest Conservation Fund grant recipients include:
The Tar River Land Conservancy: Tar River Land Conservancy aims to purchase the Bowers Tract, consisting of 244 forested acres and 60 acres of agricultural upland fields. Fifty-four percent (219 acres) of the property is situated within the 100-year-old floodplain of Swift Creek, a major tributary of the Tar River. Adjoining the property, Swift Creek provides a habitat for numerous rare, threatened, and endangered aquatic species, including the federally protected Carolina Madtom, Tar River Spiny Mussel, and Neuse River Waterdog.
Three Rivers Land Conservancy: Three Rivers Land Conservancy aims to acquire 440 acres of bottomland hardwood forest adjacent to the Little River and Uwharrie National Forest in Montgomery County, North Carolina. The Little River Buffer and Cliffs natural areas are located on the property. Federally endangered Northern Long Eared Bat and the threatened Oak Toad, Alewife, and Blue Back Herring are all present within this forest acreage.
The Virginia Outdoors Foundation: The Virginia Outdoors Foundation aims to acquire the Turner Tract which lies on the state scenic Nottoway River near Cary's Bridge. This tract contains 134 acres of bottomland hardwoods (111 acres of general hardwoods and 23 acres of Cypress-Tupelo) which will be designated as "old growth" as well as hundreds of acres of working forest. This land contributes to the protected corridor on the Nottoway River and its conservation will support the effort to protect this unique and fragile Virginia resource with a “National Wild and Scenic River” designation. The balance of the tract will remain in working forest and/or agricultural use.
The Conservation Fund: The Conservation Fund will protect 1,915 acres dominated by native bottomland hardwoods, forested wetlands, and loblolly pine along the Nottoway River in Sussex County, Virginia. This project will add to the corridor of protected land along the Nottoway River with 3.5 miles of frontage along the Nottoway where federally endangered Roanoke Logperch and Dwarf Wedge Mussel are found. The property also features 2.5 miles of frontage on Black Branch Swamp, where over 220 acres of forested wetlands and 400 acres of bottomland hardwoods reside. Sustainable forest management and restoration to native longleaf pine and pine savanna on the property will help create a habitat for endangered species such as the Red-Cockaded Woodpecker. Once transferred to the Virginia Department of Wildlife Resources, the property will be open for hunting, hiking, fishing, boating, and wildlife watching.
Ducks Unlimited: Ducks Unlimited aims to acquire a total of 292 acres in Bertie and Gates counties in North Carolina, under two separate tracts - the Crawford Tract and the Gasking Swamp Tract. The Crawford Tract is home to the Red-Cockaded Woodpecker and will expand the adjacent (on 3 sides) Chowan Swamp Game Land, which is located in one of the most important river basins for anadromous fishes in North Carolina. The Gasking Swamp Tract will expand the adjacent Bertie County Game Land, which helps protect portions of the Cashie River Swamps’ small creeks, floodplain wetlands, and Significant Natural Heritage Areas. These tracts provide important travel corridors for black bears along the Cashie River and are recognized as a “Global Important Bird Area.”
“The Endowment continues to support the efforts of the Enviva Forest Conservation Fund. These long-term investments promote conservation, biological diversity, and ecosystem sustainability in these areas of North Carolina and Virginia,” said Teal Edelen, Program Officer at the U.S. Endowment for Forestry and Communities. “These grants support sources of clean air and water, protect threatened wildlife and plant life, and provide great opportunities for recreation in these areas.”
About the Enviva Forest Conservation Fund
The Enviva Forest Conservation Fund is a $5 million, 10-year program established by Enviva in December 2015 to protect environmentally sensitive bottomland and wetland forests. Administered by the U.S. Endowment for Forestry and Communities, the Fund awards grants annually to nonprofit organizations and government agencies for conservation projects. Learn more at http://envivaforestfund.org.
About the U.S. Endowment for Forestry and Communities
The U.S. Endowment for Forestry and Communities is a not-for-profit public charity working collaboratively with partners in the public and private sectors to advance systemic, transformative, and sustainable change for the health and vitality of the nation’s working forests and forest-reliant communities. To learn more about the Endowment, please visit our website at www.usendowment.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920006011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
